In summary, Serpina3c inhibits the Hif1α-glycolysis pathway and reduces de novo lipogenesis (DNL) and LD secretion in adipocytes by binding to Nrf2, thereby improving HFD-induced lipid metabolism disorders and alleviating adipose tissue macrophage inflammation. The gene discussed is NFE2L2; the disease is Disorder of lipid metabolism.